Purkinje

New Study Shows Intraocular Lens Centration and Stability May Be Improved When ZEPTO Capsulotomy Platform is Used with Purkinje Reflections

Retrieved on: 
Wednesday, June 15, 2022
Cataract, Eye, Intraocular lens, Journal, PPC, Cornea, Technology, Centricity, Trial of the century, LinkedIn, Surgeon, Obfuscation, Twitter, Patient, Veterinary medicine, Medical imaging, IOL, Purkinje, P4, Facebook

It explains how surgeons may use the relationship between P1 and P4 Purkinje reflections to identify reliable markers for capsulotomy centration, and then create an automated capsulotomy using ZEPTO's precision pulse capsulotomy (PPC) technology.

Key Points: 
  • It explains how surgeons may use the relationship between P1 and P4 Purkinje reflections to identify reliable markers for capsulotomy centration, and then create an automated capsulotomy using ZEPTO's precision pulse capsulotomy (PPC) technology.
  • The study underscores the importance of centering the Intraocular Lens (IOL) on the patient's visual axis, in conjunction with creating a 360-degree capsular overlap during surgery to maintain optimal lens positioning and stability.
  • Purkinje images are light reflections off the cornea and the lens that are often used for improving IOL centration.
  • There are four Purkinje reflections, labeled P1 through P4, and they can determine the patient's point of fixation to assist with optimal capsulotomy centration.

Azafaros Presents Positive Clinical and Preclinical Data Supporting Development of Lead Compound AZ-3102 in Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Conference

Retrieved on: 
Monday, February 14, 2022
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, LSD, Diarrhea, Patient, GCS, Tremor, Glycosphingolipid, Brain, Animal, Enzyme, CA, Lists of diseases, GM2 gangliosidoses, Neuropathology, Safety, Posture, Infant, Therapy, Pharmacology, Cerebrospinal fluid, NPC, GM1, Gait, Scale, Courage, Survival, Purkinje cell, Disease, CSF, Blood, Assessment, Metabolism, Niemann–Pick disease, Pharmacokinetics, GBA2, SARA, Pharmaceutical industry, Purkinje, Ataxia, Sandhoff disease

Azafaros B.V. announced positive clinical data from its first-in-human Phase 1 study with AZ-3102, the companys lead program in development as a potential treatment for pediatric neurogenetic lysosomal storage disorders (LSDs).

Key Points: 
  • Azafaros B.V. announced positive clinical data from its first-in-human Phase 1 study with AZ-3102, the companys lead program in development as a potential treatment for pediatric neurogenetic lysosomal storage disorders (LSDs).
  • All four presentations were made at the 18th Annual WORLDSymposium, held February 7 11, 2022, in San Diego, CA.
  • AZ-3102 is designed to selectively inhibit two enzymes involved in glycosphingolipid metabolism, called glucosylceramide synthase (GCS) and non-lysosomal glucosylceramidase (GbA2).
  • Stefano Portolano, Chief Executive Officer of Azafaros, stated, The presentations at this years WORLDSymposium conference demonstrate the exciting potential of AZ-3102 in rare metabolic diseases.

Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy Meeting

Retrieved on: 
Thursday, October 21, 2021
Safety, Phenylalanine, RNA transfection, Method, TI, LAMP1, Lance Inc., Prevalence, GLP, MPS, Hunter syndrome, Disease, PKU, Failure, PAH, Dose, Hematopoietic stem cell transplantation, Paroxysmal nocturnal hemoglobinuria, CNS, Glycogen storage disease, Phenix, Patient, ESGCT, Private Securities Litigation Reform Act, II, Clinical trial, Antibody, SEC, MPS II, Microdeletion syndrome, Cell, Purkinje, PNH, Lance, Conference, Brain, Immunoglobulin G, Company, I2S, Cell Loss Priority, COVID-19, Gene, ASHG, Nasdaq, Therapy, Population, GLOBE, Cerebellum, European Society of Gene and Cell Therapy, Liver, Gene editing, Hepatocyte, Vaccine, Pharmaceutical industry, Medical imaging, Dietary supplement

BEDFORD, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) --  Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today four presentations of preclinical data spanning its clinical-stage gene therapy program for mucopolysaccharidosis type II (MPS II, or Hunter syndrome), clinical-stage gene editing program for phenylketonuria (PKU), GTx-mAb program for paroxysmal nocturnal hemoglobinuria (PNH) and assays to evaluate levels of pre-existing antibodies to the Company’s adeno-associated viral vectors (AAVHSCs) during the 2021 European Society for Gene & Cell Therapy Virtual Conference (ESGCT).

Key Points: 
  • gene therapy candidate for MPS II, and showcased gene editing data in the PKU and humanized murine models, including on- and off-target assessment confirming the precision of our nuclease-free in vivo gene editing.
  • Encouraging data from our GTx-mAb platform showed a single dose resulted in sustained and robust expression of full-length antibodies from the liver consistent with anti-C5 therapeutics.
  • Further, we presented details of the methods of our neutralizing antibody assays used in our clinical trial screening.
  • Both methods are used in the screening phase of Homologys HMI-102 gene therapy pheNIX clinical trial to determine patient eligibility based on pre-existing Nabs.

RE Ranger Launches Groundbreaking RIACT A.I.™ Lens Technology

Retrieved on: 
Thursday, August 19, 2021
Shift, Industry, Collection, A.I, Artificiality, Clay, Visual acuity, GM, Artificial intelligence, Lens, Bright Light, Perception, Purkinje, Telescopic sight

RANDOLPH, Mass., Aug. 19, 2021 /PRNewswire/ --Today, performance eyewear brand, RE Ranger is thrilled to announce the launch of the all-new groundbreaking RIACT A.I.

Key Points: 
  • RANDOLPH, Mass., Aug. 19, 2021 /PRNewswire/ --Today, performance eyewear brand, RE Ranger is thrilled to announce the launch of the all-new groundbreaking RIACT A.I.
  • "This is the first time that RE Ranger has utilized Artificial Intelligence to create performance shooting lenses," says Sarah Dacko, RE Ranger GM.
  • "With Artificial Intelligence we were able to test and optimize one billion different lens variations to specifically formulate the precise lenses in the RIACT A.I.
  • But with the all-new RIACT A.I.lens technology, you can increase acuity and contrast together."